Cullinan Oncology Inc. (CGEM)
Cullinan Oncology Statistics
Share Statistics
Cullinan Oncology has 58.51M shares outstanding. The number of shares has increased by 1.52% in one year.
| Shares Outstanding | 58.51M |
| Shares Change (YoY) | 1.52% |
| Shares Change (QoQ) | 0.49% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 35.47M |
| Failed to Deliver (FTD) Shares | 300 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 9.78M, so 16.8% of the outstanding shares have been sold short.
| Short Interest | 9.78M |
| Short % of Shares Out | 16.8% |
| Short % of Float | 26.56% |
| Short Ratio (days to cover) | 15.94 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -3.33. Cullinan Oncology's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -3.33 |
| PS Ratio | 0 |
| Forward PS | 1.8 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Cullinan Oncology.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.53, with a Debt / Equity ratio of 0.
| Current Ratio | 13.53 |
| Quick Ratio | 13.53 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.38M |
| Employee Count | 111 |
| Asset Turnover | null |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -14.12M |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -54.59% in the last 52 weeks. The beta is -0.11, so Cullinan Oncology's price volatility has been lower than the market average.
| Beta | -0.11 |
| 52-Week Price Change | -54.59% |
| 50-Day Moving Average | 9.17 |
| 200-Day Moving Average | 14.1 |
| Relative Strength Index (RSI) | 37.99 |
| Average Volume (20 Days) | 455.49K |
Income Statement
| Revenue | n/a |
| Gross Profit | -310K |
| Operating Income | -191.09M |
| Net Income | -153.16M |
| EBITDA | -190.34M |
| EBIT | -190.65M |
| Earnings Per Share (EPS) | -3.69 |
Balance Sheet
The company has 83M in cash and 2.15M in debt, giving a net cash position of 80.85M.
| Cash & Cash Equivalents | 83M |
| Total Debt | 2.15M |
| Net Cash | 80.85M |
| Retained Earnings | -368.24M |
| Total Assets | 621.82M |
| Working Capital | 384.02M |
Cash Flow
In the last 12 months, operating cash flow was -145.3M and capital expenditures 0, giving a free cash flow of -145.3M.
| Operating Cash Flow | -145.3M |
| Capital Expenditures | 0 |
| Free Cash Flow | -145.3M |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CGEM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CGEM is $31.5, which is 303.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $31.5 |
| Price Target Difference | 303.3% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | 7.2 |
| Piotroski F-Score | 1 |